Core Viewpoint - Sacco System, an Italian biotechnology company, has established a subsidiary named Siyike in Shanghai to deepen its integration into the Chinese probiotic market [1]. Group 1: Company Overview - Sacco System is a globally recognized biotechnology enterprise with products including lactic acid starters, probiotics, postbiotics, and enzyme preparations, operating in over 110 countries and regions [1]. - The company initiated its Asia-Pacific strategy in 2018, entering markets in Singapore, Japan, and Australia, and the opening of the Shanghai subsidiary marks the preliminary completion of its integrated "R&D - Production - Market" layout in the region [1]. Group 2: Market Insights - The Chinese probiotic market has been rapidly developing, becoming one of the most dynamic markets globally. According to Frost & Sullivan, the clinical probiotic market in China is projected to grow from approximately 6.5 billion yuan in 2022 to about 7.5 billion yuan in 2024, with an expected market size of around 10 billion yuan by 2028, reflecting a compound annual growth rate (CAGR) of 7.5% [1]. - The growth is driven by the "Healthy China" strategy and increasing consumer health awareness, leading to a rising demand for functional foods such as probiotics [1]. Group 3: Strategic Collaborations - Siyike has begun collaborations with Chinese brands such as Mengniu, serving both brand owners and contract manufacturers [2]. - The company aims to promote deep integration of Sino-European technology through a "dual-engine innovation" model, establishing a joint R&D platform to develop probiotics and fermentation technologies that align with Chinese dietary culture and health needs [2]. - Additionally, Siyike plans to conduct research on microbiomes that combines Italian fermentation techniques with local Chinese practices to create products and solutions that are more suited to the local market [2].